MX2018013701A - Derivados de piridinilo, composiciones farmaceuticas y sus usos como inhibidores aoc3. - Google Patents

Derivados de piridinilo, composiciones farmaceuticas y sus usos como inhibidores aoc3.

Info

Publication number
MX2018013701A
MX2018013701A MX2018013701A MX2018013701A MX2018013701A MX 2018013701 A MX2018013701 A MX 2018013701A MX 2018013701 A MX2018013701 A MX 2018013701A MX 2018013701 A MX2018013701 A MX 2018013701A MX 2018013701 A MX2018013701 A MX 2018013701A
Authority
MX
Mexico
Prior art keywords
pharmaceutical compositions
pyridinyl derivatives
aoc3 inhibitors
aoc3
inhibitors
Prior art date
Application number
MX2018013701A
Other languages
English (en)
Inventor
Peters Stefan
Blum Andreas
Godbout Cédrickx
P Hehn Joerg
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MX2018013701A publication Critical patent/MX2018013701A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La invención se refiere a nuevos derivados de piridinilo de la fórmula (I) (VER FORMULA) en donde R1 y A son como se definen en la descripción y las reivindicaciones, a su uso como medicamentos, a los métodos para su uso terapéutico y a las composiciones farmacéuticas que los contienen.
MX2018013701A 2016-05-12 2017-05-08 Derivados de piridinilo, composiciones farmaceuticas y sus usos como inhibidores aoc3. MX2018013701A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16169356 2016-05-12
PCT/EP2017/060890 WO2017194453A1 (en) 2016-05-12 2017-05-08 Pyridinyl derivatives, pharmaceutical compositions and uses thereof as aoc3 inhibitors

Publications (1)

Publication Number Publication Date
MX2018013701A true MX2018013701A (es) 2019-05-02

Family

ID=55967162

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018013701A MX2018013701A (es) 2016-05-12 2017-05-08 Derivados de piridinilo, composiciones farmaceuticas y sus usos como inhibidores aoc3.

Country Status (32)

Country Link
US (1) US9926292B2 (es)
EP (1) EP3455216B1 (es)
JP (1) JP6639702B2 (es)
KR (1) KR20190003995A (es)
CN (1) CN109153664B (es)
AR (1) AR108462A1 (es)
AU (1) AU2017262707B2 (es)
CA (1) CA3023805A1 (es)
CL (1) CL2018003158A1 (es)
CO (1) CO2018012020A2 (es)
CY (1) CY1123744T1 (es)
DK (1) DK3455216T3 (es)
EA (1) EA037188B1 (es)
ES (1) ES2844926T3 (es)
HR (1) HRP20202078T1 (es)
HU (1) HUE053312T2 (es)
IL (1) IL262662B (es)
JO (1) JOP20170115B1 (es)
LT (1) LT3455216T (es)
MA (1) MA44965B1 (es)
MX (1) MX2018013701A (es)
PE (1) PE20190151A1 (es)
PH (1) PH12018502376A1 (es)
PL (1) PL3455216T3 (es)
PT (1) PT3455216T (es)
RS (1) RS61256B1 (es)
SA (1) SA518400393B1 (es)
SG (1) SG11201809687TA (es)
SI (1) SI3455216T1 (es)
TW (1) TWI746551B (es)
UA (1) UA121930C2 (es)
WO (1) WO2017194453A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019254371A1 (en) 2018-04-17 2020-10-08 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
WO2020083264A1 (zh) * 2018-10-22 2020-04-30 广东东阳光药业有限公司 胍类衍生物及其用途
KR20210084537A (ko) * 2018-10-29 2021-07-07 베링거 인겔하임 인터내셔날 게엠베하 피리디닐 설폰아미드 유도체, 약제학적 조성물 및 이의 용도
WO2021083209A1 (en) 2019-10-29 2021-05-06 Eccogene (Shanghai) Co., Ltd. Ssao inhibitors and use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19518073A1 (de) * 1995-05-17 1996-11-21 Hoechst Ag Substituierte Benzyloxycarbonylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
CA2536954C (en) * 2003-08-29 2012-11-27 Exelixis, Inc. C-kit modulators and methods of use
CA2575411A1 (en) * 2004-07-27 2006-02-02 Astellas Pharma Inc. Thiazole derivatives having vap-1 inhibitory activity
PL2479165T3 (pl) * 2009-09-16 2018-05-30 Astellas Pharma Inc. Związek glicynowy
ES2628850T3 (es) * 2011-03-15 2017-08-04 Astellas Pharma Inc. Compuesto de guanidina
JP6809464B2 (ja) 2015-08-06 2021-01-06 宇部興産株式会社 置換グアニジン誘導体

Also Published As

Publication number Publication date
PE20190151A1 (es) 2019-01-22
CO2018012020A2 (es) 2018-11-13
DK3455216T3 (da) 2021-01-18
JOP20170115B1 (ar) 2021-08-17
RS61256B1 (sr) 2021-01-29
PT3455216T (pt) 2021-01-18
AU2017262707B2 (en) 2020-11-19
EP3455216A1 (en) 2019-03-20
KR20190003995A (ko) 2019-01-10
US20170327483A1 (en) 2017-11-16
US9926292B2 (en) 2018-03-27
CA3023805A1 (en) 2017-11-16
JP6639702B2 (ja) 2020-02-05
CN109153664B (zh) 2021-07-16
PH12018502376B1 (en) 2019-04-08
SI3455216T1 (sl) 2021-02-26
UA121930C2 (uk) 2020-08-10
EA201892539A1 (ru) 2019-06-28
CL2018003158A1 (es) 2019-01-18
HRP20202078T1 (hr) 2021-02-19
NZ746586A (en) 2021-08-27
TWI746551B (zh) 2021-11-21
EA037188B1 (ru) 2021-02-17
IL262662B (en) 2021-07-29
AU2017262707A1 (en) 2018-10-11
CN109153664A (zh) 2019-01-04
MA44965B1 (fr) 2021-02-26
AR108462A1 (es) 2018-08-22
EP3455216B1 (en) 2020-11-04
SG11201809687TA (en) 2018-11-29
WO2017194453A1 (en) 2017-11-16
MA44965A (fr) 2019-03-20
TW201805278A (zh) 2018-02-16
IL262662A (en) 2018-12-31
ES2844926T3 (es) 2021-07-23
PH12018502376A1 (en) 2019-04-08
JP2019519495A (ja) 2019-07-11
CY1123744T1 (el) 2022-05-27
PL3455216T3 (pl) 2021-05-17
SA518400393B1 (ar) 2021-09-08
HUE053312T2 (hu) 2021-07-28
LT3455216T (lt) 2021-01-11

Similar Documents

Publication Publication Date Title
PH12018502747A1 (en) Boronic acid derivatives and therapeutic uses thereof
MX2019005379A (es) Derivado de pirazolo-heteroarilo, metodo de preparacion y uso medico del mismo.
PH12018500591A1 (en) Heterocyclic compounds and uses thereof
MD20170016A2 (ro) Compuşi aminopirimidinici ca inhibitori JAK
PH12018502515B1 (en) New piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them
EA033266B1 (ru) Гидроксисложноэфирные производные, способ их получения и фармацевтические композиции, содержащие их
TW201613911A (en) Heterocyclic compounds and uses thereof
GEP201706619B (en) New thienopyrimidine derivatives, a process for their preparation and pharmaceutical composition containing them
MD20170070A2 (ro) Derivaţi de chinazolină utilizaţi în tratamentul HIV
UA116648C2 (uk) Фумарати як проліки та їх застосування при лікуванні різних захворювань
MX2016015565A (es) Ciertos inhibidores de la proteina quinasa.
PH12014501514A1 (en) New azetidine derivatives, pharmaceutical compositions and uses thereof
PH12018500446A1 (en) Pyridinone dicarboxamide for use as bromodomain inhibitors
TW201613864A (en) Novel compounds
MX2020011818A (es) Derivados de piridincarboxamida, su metodo de preparacion y sus usos farmaceuticos.
PH12016501462A1 (en) Neprilysin inhibitors
PH12018502376B1 (en) Pyridinyl derivatives, pharmaceutical compositions and uses thereof as aoc3 inhibitors
MA40583A (fr) Nouveaux activateurs de la guanylate cyclase soluble et leur utilisation
AU2017269673A1 (en) Pyridine dicarboxamide derivatives as bromodomain inhibitors
MY181641A (en) Amino pyran ring derivative and composition and use thereof
MX2015011614A (es) Derivados de pirrolidina, composiciones farmaceuticas que los contienen, y su uso en terapia.
MX2016004934A (es) Derivados de aminotetralina y aminoindano, composiciones farmaceuticas que los contienen, y su uso en terapia.
EA032927B1 (ru) Производные гидроксиалкилпиперазина в качестве модуляторов cxcr3 рецептора
NZ710291A (en) 2-substituted-6-biarylmethylamino-9-cyclopentyl-9h-purine derivatives, use thereof as medicaments, and pharmaceutical compositions
MX2017009292A (es) Derivados de (r)-2-metil-piperazina como moduladores del receptor cxcr3.